狼疮低疾病活动状态(LLDAS)在BLISS-52和BLISS-76贝利尤单抗III期试验中可区分应答者
该研究对BLISS-52和BLISS-76贝利尤单抗治疗系统性红斑狼疮(SLE)的III期试验数据进行事后分析,评估LLDAS的区分能力。第52周时,贝利尤单抗10 mg/kg组达到LLDAS的患者比例显著高于安慰剂组(BLISS-52:12.5% vs 5.8%,OR 2.32,p=0.02;BLISS-76:14.4% vs 7.8%,OR 1.98,p=0.04)。基线疾病活动度较高的亚组中,贝利尤单抗与安慰剂间LLDAS attainment差异更大。结论支持LLDAS作为SLE临床试验结局指标的有效性。
要点
- 贝利尤单抗10 mg/kg组第52周LLDAS attainment显著高于安慰剂组。
- 基线高疾病活动度亚组中,LLDAS区分贝利尤单抗与安慰剂的差异更大。
- LLDAS可作为SLE临床试验中区分治疗应答的结局指标。
核心结论
- LLDAS能够在BLISS-52和BLISS-76试验中区分贝利尤单抗10 mg/kg与安慰剂。
- 研究结果支持LLDAS作为SLE临床试验结局指标的有效性。
研究设计与样本
- 对BLISS-52和BLISS-76贝利尤单抗治疗SLE的III期试验数据进行事后分析。
- 在第52周评估LLDAS attainment、贝利尤单抗与安慰剂组间区分度及高疾病活动度亚组效应。
- 使用描述性统计、χ2检验和逻辑回归进行分析。
主要发现
- BLISS-52中,达到SLE应答指数-4且同时达到LLDAS的患者在贝利尤单抗10 mg/kg组占17.0%。
- BLISS-76中,达到SLE应答指数-4且同时达到LLDAS的患者在贝利尤单抗10 mg/kg组占19.3%。
- BLISS-52第52周LLDAS attainment:贝利尤单抗10 mg/kg组12.5% vs 安慰剂组5.8%,OR 2.32,p=0.02。
- BLISS-76第52周LLDAS attainment:贝利尤单抗10 mg/kg组14.4% vs 安慰剂组7.8%,OR 1.98,p=0.04。
- 基线疾病活动度较高的亚组中,贝利尤单抗10 mg/kg与安慰剂间第52周LLDAS attainment差异大于总体组。
关键数值与推荐
- LLDAS attainment定义为达到狼疮低疾病活动状态。
- BLISS-52:贝利尤单抗10 mg/kg组12.5% vs 安慰剂组5.8%达到LLDAS,OR 2.32,p=0.02。
- BLISS-76:贝利尤单抗10 mg/kg组14.4% vs 安慰剂组7.8%达到LLDAS,OR 1.98,p=0.04。
临床怎么用
- 在SLE临床试验中可采用LLDAS作为区分治疗应答的结局指标。
- 对基线疾病活动度较高的SLE患者,LLDAS可能更明显地区分贝利尤单抗与安慰剂的疗效差异。
局限性
- 本研究为对BLISS-52和BLISS-76试验数据的事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We evaluated the discriminant capacity of the Lupus Low Disease Activity State (LLDAS) in post-hoc analysis of data from the BLISS-52 and BLISS-76 trials of belimumab in systemic lupus erythematosus (SLE). METHODS: LLDAS attainment, discrimination between belimumab and placebo arms, and the effects in subgroups with high disease activity at recruitment were evaluated at week 52 using appropriate descriptive statistics, χ2 test and logistic regression. RESULTS: At week 52, for belimumab 10 mg/kg, 17.0% and 19.3% of patients who achieved a Systemic Lupus Erythematosus Responder Index-4 also attained LLDAS in BLISS-52 and BLISS-76, respectively. Significantly more patients attained LLDAS on belimumab 10 mg/kg compared with placebo (12.5% vs 5.8%, OR 2.32, p=0.02 for BLISS-52; 14.4% vs 7.8%, OR 1.98, p=0.04 for BLISS-76). In a subgroup analysis, the difference in week 52 LLDAS attainment between belimumab 10 mg/kg and placebo was greater in patients who had higher disease activity at baseline, compared with the overall group. CONCLUSIONS: LLDAS was able to discriminate belimumab 10 mg/kg from placebo in the BLISS-52 and BLISS-76 trials. Our findings support the validity of LLDAS as an outcome measure in SLE clinical trials.
引用
- Oon S, Huq M, Golder V, et al. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. Ann Rheum Dis. 2019. PMID: 30679152. doi:10.1136/annrheumdis-2018-214427
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。